AC Immune partner J&J pauses Alzheimer’s trial enrollment
AC Immune (ACIU) has disclosed that its partner Janssen Pharmaceuticals of Johnson & Johnson (JNJ) has temporarily paused enrollments in a mid-stage trial for their jointly developed Alzheimer’s candidate ACI-35.030/JNJ-2056. The companies are advancing ACI-35.030/JNJ-2056 as part of a licensing ...